Regeneron Pharmaceuticals, Inc. Share Price

Equities

REGN

US75886F1075

Biotechnology & Medical Research

Market Closed - Nasdaq 01:30:00 25/05/2024 am IST 5-day change 1st Jan Change
985 USD +0.45% Intraday chart for Regeneron Pharmaceuticals, Inc. +0.28% +12.15%
Sales 2024 * 13.82B 1,148B Sales 2025 * 14.93B 1,240B Capitalization 106B 8,825B
Net income 2024 * 3.96B 329B Net income 2025 * 4.42B 367B EV / Sales 2024 * 7.03 x
Net cash position 2024 * 9.08B 754B Net cash position 2025 * 14.86B 1,234B EV / Sales 2025 * 6.12 x
P/E ratio 2024 *
29.1 x
P/E ratio 2025 *
26 x
Employees 13,677
Yield 2024 *
-
Yield 2025 *
-
Free-Float 78.42%
More Fundamentals * Assessed data
Dynamic Chart
Regeneron Pharmaceuticals Says GN7075 Plus Libtayo Shows Anti-Tumor Responses in Microsatellite Stable Colorectal Cancer MT
Regeneron Pharmaceuticals, Inc. Announces Positive New Results from an Ongoing Phase 1/2 Trial Evaluating its First-in-Class Costimulatory Bispecific Antibody, REGN7075 CI
Regeneron Pharmaceuticals Insider Sold Shares Worth $1,855,489, According to a Recent SEC Filing MT
Regeneron, Sanofi Disclose Positive Results for Lung Disease Treatment Candidate MT
Jefferies Raises Regeneron Pharmaceuticals' Price Target to $1,125 From $1,115 MT
Piper Sandler Adjusts Price Target on Regeneron Pharmaceuticals to $1,000 From $1,000.25 MT
Regeneron Pharmaceuticals Insider Sold Shares Worth $22,355,714, According to a Recent SEC Filing MT
Regeneron Pharmaceuticals Insider Sold Shares Worth $48,636,545, According to a Recent SEC Filing MT
Sector Update: Health Care Stocks Mixed Late Afternoon MT
Jefferies Raises Regeneron Pharmaceuticals' Price Target to $1,115 From $1,060 MT
Regeneron Pharmaceuticals Insider Sold Shares Worth $35,207,110, According to a Recent SEC Filing MT
Transcript : Regeneron Pharmaceuticals, Inc. Presents at 2024 RBC Capital Markets Global Healthcare Conference, May-14-2024 09:00 AM
Regeneron, Sanofi Get Speedy FDA Review of Dupixent in Younger CRSwNP Group DJ
Regeneron Pharmaceuticals, Sanofi Say FDA Accepts Dupixent Supplemental Application for Priority Review MT
Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts for Priority Review the Supplemental Biologics License Application for Dupixent CI
More news
1 day+0.45%
1 week+0.28%
Current month+10.59%
1 month+8.66%
3 months+0.39%
6 months+23.39%
Current year+12.15%
More quotes
1 week
975.73
Extreme 975.73
997.87
1 month
875.23
Extreme 875.225
997.87
Current year
871.39
Extreme 871.39
998.33
1 year
684.81
Extreme 684.805
998.33
3 years
492.13
Extreme 492.13
998.33
5 years
271.37
Extreme 271.37
998.33
10 years
269.50
Extreme 269.5
998.33
More quotes
Managers TitleAgeSince
Founder 64 08/88/08
Chief Executive Officer 71 08/88/08
Director of Finance/CFO 54 01/03/01
Members of the board TitleAgeSince
Director/Board Member 71 12/10/12
Chief Executive Officer 71 08/88/08
Director/Board Member 82 01/91/01
More insiders
Date Price Change Volume
24/24/24 985 +0.45% 259,279
23/24/23 980.6 -0.33% 315,734
22/24/22 983.8 -1.02% 308,654
21/24/21 994 +0.68% 331,610
20/24/20 987.3 +0.51% 317,884

Delayed Quote Nasdaq, May 25, 2024 at 01:30 am IST

More quotes
Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows: - revenues from product sales (56.6%); - revenues from collaboration agreements (40.4%): collaboration with Sanofi (58.1% of revenues), Bayer (29.1%) and Roche (12.8%); - other (3%): primarily revenues from sales of technology licenses and subcontracted research services. At the end of 2022, the group had a portfolio of approximately 35 products in clinical development.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
27
Last Close Price
985 USD
Average target price
1,042 USD
Spread / Average Target
+5.78%
Consensus